Burrill & Company

Neos Therapeutics, Inc. is a pharmaceutical company focused on the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD) using its specialized drug delivery technology. The company's product lineup includes extended-release medications such as Adzenys XR-ODT and Cotempla XR-ODT, both designed for ADHD treatment, along with Adzenys ER and a generic version of Tussionex, which is used for cough relief. Neos also has a clinical-stage product candidate, NT0502, aimed at treating neurological conditions associated with excessive salivation. Established in 2009 and headquartered in Grand Prairie, Texas, Neos Therapeutics operates a state-of-the-art manufacturing facility and emphasizes high-quality products to meet critical medical needs in the United States.

Nora Therapeutics, Inc. is a biotechnology company based in Palo Alto, California, specializing in therapeutics aimed at addressing unmet needs in reproductive medicine. The company’s lead product, NT100, is a biologic agent designed to enhance pregnancy success rates for women who have experienced multiple unsuccessful in vitro fertilization (IVF) attempts or recurrent miscarriages. NT100 mimics a naturally occurring protein found in the female reproductive tract and works by optimizing maternal-fetal immune tolerance, thereby improving the chances of embryo implantation and pregnancy maintenance. Founded in 1992, Nora Therapeutics is dedicated to providing innovative solutions for women facing challenges in reproductive health.

Neos Therapeutics, Inc. is a pharmaceutical company focused on the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD) using its specialized drug delivery technology. The company's product lineup includes extended-release medications such as Adzenys XR-ODT and Cotempla XR-ODT, both designed for ADHD treatment, along with Adzenys ER and a generic version of Tussionex, which is used for cough relief. Neos also has a clinical-stage product candidate, NT0502, aimed at treating neurological conditions associated with excessive salivation. Established in 2009 and headquartered in Grand Prairie, Texas, Neos Therapeutics operates a state-of-the-art manufacturing facility and emphasizes high-quality products to meet critical medical needs in the United States.

BetterDoctor, Inc. is a company based in San Francisco, California, that specializes in developing web and mobile applications to assist users in finding healthcare providers. Founded in 2011, BetterDoctor allows users to specify the type of doctor they need and select their insurance plan to view a list of verified healthcare professionals. The company's platform provides accurate provider data to health plans, health systems, and various organizations through its API, facilitating the search for doctors and improving healthcare access. BetterDoctor's services have reached millions of users, powering numerous health plans and companies by enhancing the transparency and reliability of doctor data. As of June 2018, BetterDoctor operates as a subsidiary of Quest Analytics, L.L.C.

NewBridge Pharmaceuticals Ltd. is a specialty therapeutics company based in Dubai, United Arab Emirates, that focuses on pharmaceuticals, biologics, and medical diagnostics. Established in 2007, the company specializes in in-licensing and commercializing healthcare products to meet the unmet medical needs of patients in the Middle East, Africa, Turkey, and the Caspian regions. NewBridge offers a range of oncology and supportive care products, including Abstral for cancer pain management, Clasteon for bone metastasis-related conditions, Sancuso for chemotherapy-induced nausea, and Oncotype DX for breast cancer recurrence assessment. Additionally, it provides metabolic care products like Gliconorm for diabetes treatment and PYLERA for H. pylori eradication. The company's portfolio further includes CNS care products like Vimpat for seizures and Neupro for Parkinson's disease, as well as immunology care products such as Cimzia for rheumatoid arthritis. By addressing critical health issues such as cancer, diabetes, and cardiovascular diseases, NewBridge Pharmaceuticals aims to enhance patient care in its targeted regions.

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company specializes in developing innovative treatments for hemophilia and other rare bleeding disorders, utilizing its engineered subcutaneous coagulation factors to promote blood clotting. This approach aims to address the inherent limitations of traditional intravenous treatments and improve patient outcomes. Catalyst's product portfolio includes Marzeptacog alfa (activated), an advanced coagulation Factor VIIa that has completed Phase II development for hemophilia A or B with inhibitors, and Dalcinonacog alfa, a next-generation Factor IX therapy that has finished Phase IIb clinical trials for hemophilia B. Additionally, the company is working on CB 2679d-GT, an early-stage gene therapy for hemophilia B, as well as other treatments targeting dry age-related macular degeneration and systemic complement inhibitors. Catalyst Biosciences has also formed strategic collaborations with Mosaic Biosciences and Biogen to enhance its research and development efforts in these therapeutic areas. The company was founded in 2002 and has a commitment to addressing unmet medical needs in coagulation and complement disorders.

Strand Life Sciences Pvt Ltd. is a clinical diagnostics and genomic profiling company based in Bengaluru, India, specializing in the development and marketing of diagnostic tests for cancer and inherited diseases. Founded in 2000, the company offers a wide range of services, including diagnostics for oncology, genetics, fertility, women's health, infectious diseases, and general wellness. Strand provides advanced bioinformatics solutions, such as variant curation and interpretation platforms, along with its StrandOmics software for actionable insights from genomic data. The firm operates a DNA sequencing lab and has established partnerships with over 100 hospitals in India, expanding its reach into the US market. Strand's innovative software, including GeneSpring and Avadis, is utilized by 1,400 research institutions worldwide. The company emphasizes personalized medicine by identifying hereditary cancer risks and enabling tailored surveillance and risk-reduction strategies for patients. With a team of approximately 200 employees, Strand Life Sciences continues to grow in response to increasing demand for its genomic testing and interpretation services.

Odyssey Thera, Inc. is a biopharmaceutical company focused on developing therapies for cancer treatment. Founded in 2002 and based in San Ramon, California, the company employs a cellular pharmacology strategy to identify and develop medicines targeting human diseases. Odyssey Thera specializes in deciphering biologically-relevant pathways in living human cells, which enhances drug discovery and improves methods for assessing environmental chemical toxicity. Its product pipeline features small molecule inhibitors designed to block key signaling nodes in cancer cells, reflecting the company's commitment to advancing innovative cancer therapies.

MabVax Therapeutics is a clinical stage biopharmaceutical company dedicated to the development and commercialization of innovative anti-cancer immunotherapies. The company leverages two main technology platforms: one involves proprietary vaccines developed at Memorial Sloan-Kettering Cancer Center, with two lead cancer vaccines currently in Phase II clinical trials targeting soft tissue sarcoma and ovarian cancer, both of which have received substantial federal grant support. The second platform is an internally developed human antibody discovery system, which focuses on the immune responses from patients who have been vaccinated against specific cancers. MabVax's leading human antibody candidate is in preclinical evaluation for potential applications in treating colon, pancreatic, and breast cancers, also backed by federal funding. The company aims to address significant unmet needs in cancer treatment through its innovative approaches and pipeline of human monoclonal antibody products.

Cobalt Technologies is a company focused on developing innovative technologies for biofuels, particularly in the production of bio-based chemicals. Founded in 2005 and headquartered in Mountain View, California, Cobalt is pioneering methods to produce low-cost, commercial-scale biobutanol, an alternative to traditional petroleum-based products. This next-generation bio n-butanol serves as an ingredient in various applications, including fuels, bio-based plastics, synthetic rubber, paints, adhesives, and solvents. By offering cost-effective substitutes to petroleum-derived chemicals, Cobalt aims to create fuels that burn cleaner and have a reduced environmental impact.

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company specializes in developing innovative treatments for hemophilia and other rare bleeding disorders, utilizing its engineered subcutaneous coagulation factors to promote blood clotting. This approach aims to address the inherent limitations of traditional intravenous treatments and improve patient outcomes. Catalyst's product portfolio includes Marzeptacog alfa (activated), an advanced coagulation Factor VIIa that has completed Phase II development for hemophilia A or B with inhibitors, and Dalcinonacog alfa, a next-generation Factor IX therapy that has finished Phase IIb clinical trials for hemophilia B. Additionally, the company is working on CB 2679d-GT, an early-stage gene therapy for hemophilia B, as well as other treatments targeting dry age-related macular degeneration and systemic complement inhibitors. Catalyst Biosciences has also formed strategic collaborations with Mosaic Biosciences and Biogen to enhance its research and development efforts in these therapeutic areas. The company was founded in 2002 and has a commitment to addressing unmet medical needs in coagulation and complement disorders.

Waterstone Pharmaceuticals, Inc. is a private company focused on the research, development, and commercialization of innovative drugs for liver, gastrointestinal, kidney, and metabolic diseases. Founded in 2009, the company has its headquarters in Wuhan, China, with additional offices in Tianmen. Waterstone's activities encompass drug discovery, the development of proprietary new chemical entities, custom development and manufacturing services, and the production of generic drugs. The company also specializes in creating a range of active pharmaceutical ingredients, intermediates, and antibody drug conjugates.

AliveCor, Inc. specializes in developing digital medical-grade electrocardiograms, enabling users to monitor their heart health through mobile technology. The company's flagship product, KardiaMobile, is a personal mobile EKG device that provides instant detection of common heart arrhythmias, along with features for blood pressure and weight tracking, as well as storage for recorded EKGs. Additionally, AliveCor offers KardiaMobile 6L, a six-lead EKG device that allows patients to share detailed EKG readings with healthcare providers. The company also operates KardiaCare, a digital health subscription service that empowers users to manage their heart health conveniently at home. Founded in 2010 and incorporated in 2011, AliveCor is headquartered in Mountain View, California, and is recognized for its innovative contributions to cardiac care through the integration of machine learning techniques.

Ceptaris Therapeutics, Inc. is a privately held specialty pharmaceutical company focused on developing a proprietary gel formulation of mechlorethamine hydrochloride for treating early-stage (stages I-IIA) mycosis fungoides, a form of Cutaneous T-Cell Lymphoma (CTCL). If approved, this investigational drug would be the first topical mechlorethamine product available for managing the signs and symptoms of this rare cancer. In addition to this primary focus, Ceptaris is also involved in developing other therapeutic products, including YT-1006, an NMDA antagonist aimed at treating neuropathic pain while minimizing side effects associated with NMDA. The company's innovative approaches enable healthcare professionals to address both dermatological and central nervous system disorders effectively.

WhiteGlove Health, Inc. is a mobile healthcare provider based in Austin, Texas, specializing in delivering primary care, preventative medical services, and support for individuals with chronic conditions directly at home and work sites. Established in 2006, the company has expanded its services to major locations including Dallas/Fort Worth, Houston, San Antonio, and Phoenix. WhiteGlove Health focuses on creating a high-quality healthcare experience while simultaneously reducing costs for health plans through decreased insurance claims and minimized unnecessary medical utilization. The clinical team, composed of board-certified nurse practitioners and registered nurses, provides comprehensive care, including at-home visits and telephonic support, particularly for high-risk patients under Medicare and Medicaid. The company’s Value-Based Care division, launched in 2014, emphasizes proactive management to reduce hospital admissions and improve patient outcomes. Additionally, WhiteGlove Health enhances its service offerings through a partnership with Glenridge Healthcare Solutions, which provides advanced analytics and technology solutions, further promoting efficient healthcare delivery across the nation.

WaveTec Vision, founded in 1997 and located in Aliso Viejo, California, specializes in advanced wavefront measurement technology for cataract surgery. The company's proprietary intraoperative aberrometer system, ORange, allows surgeons to measure the eye and enhance surgical outcomes in real-time. By facilitating the convergence of refractive and cataract surgery, WaveTec Vision aims to improve the overall efficacy and precision of these procedures, ultimately benefiting patient care and satisfaction.

Cobalt Technologies is a company focused on developing innovative technologies for biofuels, particularly in the production of bio-based chemicals. Founded in 2005 and headquartered in Mountain View, California, Cobalt is pioneering methods to produce low-cost, commercial-scale biobutanol, an alternative to traditional petroleum-based products. This next-generation bio n-butanol serves as an ingredient in various applications, including fuels, bio-based plastics, synthetic rubber, paints, adhesives, and solvents. By offering cost-effective substitutes to petroleum-derived chemicals, Cobalt aims to create fuels that burn cleaner and have a reduced environmental impact.

Virdia, formerly known as HCL CleanTech, specializes in the development of cellulosic sugars and lignin derived from lignocellulosic biomass for applications in renewable chemicals, bio-energy, and nutrition. The company utilizes its proprietary CASE™ process, which efficiently converts a variety of feedstocks, including wood, energy crops, and agricultural residues, into refined sugars and lignin. This innovative, low-temperature method maximizes sugar yields while maintaining a minimal environmental impact through the nearly complete recycling of acids and solvents used during production. Virdia is guided by an experienced management team with extensive backgrounds in corn processing, chemicals, and biochemicals.

ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics aimed at treating immune deficiencies and infectious diseases in the United States. The company offers a range of products, including BIVIGAM and ASCENIV, both intravenous immune globulin therapies for primary humoral immunodeficiency, as well as Nabi-HB, which is used for acute exposure to Hepatitis B. ADMA is also involved in the development of additional plasma-derived therapeutics, particularly targeting infections like S. pneumonia. To support its operations, the company runs FDA-licensed source plasma collection facilities known as ADMA BioCenters, which contribute to the supply of plasma necessary for its product manufacturing. ADMA Biologics distributes its products through independent distributors, sales agents, specialty pharmacies, and other healthcare providers. Founded in 2004 and based in Ramsey, New Jersey, ADMA is dedicated to serving niche patient populations, particularly those with compromised immune systems.

Ceptaris Therapeutics, Inc. is a privately held specialty pharmaceutical company focused on developing a proprietary gel formulation of mechlorethamine hydrochloride for treating early-stage (stages I-IIA) mycosis fungoides, a form of Cutaneous T-Cell Lymphoma (CTCL). If approved, this investigational drug would be the first topical mechlorethamine product available for managing the signs and symptoms of this rare cancer. In addition to this primary focus, Ceptaris is also involved in developing other therapeutic products, including YT-1006, an NMDA antagonist aimed at treating neuropathic pain while minimizing side effects associated with NMDA. The company's innovative approaches enable healthcare professionals to address both dermatological and central nervous system disorders effectively.

AliveCor, Inc. specializes in developing digital medical-grade electrocardiograms, enabling users to monitor their heart health through mobile technology. The company's flagship product, KardiaMobile, is a personal mobile EKG device that provides instant detection of common heart arrhythmias, along with features for blood pressure and weight tracking, as well as storage for recorded EKGs. Additionally, AliveCor offers KardiaMobile 6L, a six-lead EKG device that allows patients to share detailed EKG readings with healthcare providers. The company also operates KardiaCare, a digital health subscription service that empowers users to manage their heart health conveniently at home. Founded in 2010 and incorporated in 2011, AliveCor is headquartered in Mountain View, California, and is recognized for its innovative contributions to cardiac care through the integration of machine learning techniques.

NewBridge Pharmaceuticals Ltd. is a specialty therapeutics company based in Dubai, United Arab Emirates, that focuses on pharmaceuticals, biologics, and medical diagnostics. Established in 2007, the company specializes in in-licensing and commercializing healthcare products to meet the unmet medical needs of patients in the Middle East, Africa, Turkey, and the Caspian regions. NewBridge offers a range of oncology and supportive care products, including Abstral for cancer pain management, Clasteon for bone metastasis-related conditions, Sancuso for chemotherapy-induced nausea, and Oncotype DX for breast cancer recurrence assessment. Additionally, it provides metabolic care products like Gliconorm for diabetes treatment and PYLERA for H. pylori eradication. The company's portfolio further includes CNS care products like Vimpat for seizures and Neupro for Parkinson's disease, as well as immunology care products such as Cimzia for rheumatoid arthritis. By addressing critical health issues such as cancer, diabetes, and cardiovascular diseases, NewBridge Pharmaceuticals aims to enhance patient care in its targeted regions.

Ferrokin Biosciences Inc. develops and markets medical devices. The company offers iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemias. The company is based in San Carlos, California.

Gevo, Inc. is a renewable fuels company based in Englewood, Colorado, focused on developing and commercializing sustainable alternatives to petroleum-based products. Founded in 2005, Gevo specializes in producing renewable fuels such as gasoline, jet fuel, and diesel, as well as chemicals derived from isobutanol, a key product made from low-carbon renewable feedstocks. The company's offerings include renewable biodiesel, sustainable aviation fuel, isobutylene, ethanol, and animal feed. Gevo is also engaged in producing renewable electricity and natural gas to support its operations. Through its various segments, Gevo conducts research and development aimed at advancing biofuels and biochemicals, including innovative technologies for the production of sustainable aviation fuel and other renewable hydrocarbon products, while actively working to reduce greenhouse gas emissions.

Endocyte, Inc. is a biopharmaceutical company focused on developing receptor-targeted therapies for cancer and inflammatory diseases. Headquartered in West Lafayette, Indiana, the company creates innovative small molecule drug conjugates (SMDCs) and companion imaging agents. Among its key products, Vintafolide is in Phase IIb clinical trials for non-small cell lung cancer, while EC1456 and EC1169 are in Phase I trials for advanced solid tumors and metastatic castration-resistant prostate cancer, respectively. Additionally, Endocyte is developing several pre-clinical candidates, including EC2629 for cancer treatment and EC2319 for inflammatory diseases. The company has established collaborations with Purdue Research Foundation and other organizations to advance its pipeline. Founded in 1995, Endocyte operates as a subsidiary of Novartis AG.

Ferrokin Biosciences Inc. develops and markets medical devices. The company offers iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemias. The company is based in San Carlos, California.

PrimeraDx, Inc. specializes in multiplexed infectious disease assays, focusing on advanced diagnostic technologies. The company offers Scalable Target Amplification Routine technology, enabling the simultaneous quantitative measurement of multiple target nucleic acids. Its product lineup includes ViraQuant, a multiplexed assay for the quantitative measurement of various viruses, as well as FungiQuant Yeast and FungiQuant Mold, which are fungal panels used in mycology testing. Additionally, PrimeraDx provides an instrument designed for the simultaneous detection and quantification of diverse target types, such as mRNA, miRNA, SNPs, and DNA. These products are utilized in various applications, including miRNA analysis, DNA methylation, quantitative genotyping, gene expression, and viral load measurement. Founded in 2004, PrimeraDx is headquartered in Mansfield, Massachusetts.

Gevo, Inc. is a renewable fuels company based in Englewood, Colorado, focused on developing and commercializing sustainable alternatives to petroleum-based products. Founded in 2005, Gevo specializes in producing renewable fuels such as gasoline, jet fuel, and diesel, as well as chemicals derived from isobutanol, a key product made from low-carbon renewable feedstocks. The company's offerings include renewable biodiesel, sustainable aviation fuel, isobutylene, ethanol, and animal feed. Gevo is also engaged in producing renewable electricity and natural gas to support its operations. Through its various segments, Gevo conducts research and development aimed at advancing biofuels and biochemicals, including innovative technologies for the production of sustainable aviation fuel and other renewable hydrocarbon products, while actively working to reduce greenhouse gas emissions.

CareDx, Inc. is a precision medicine company that specializes in developing and commercializing innovative healthcare solutions for transplant patients and their caregivers. The company offers a range of molecular diagnostics products, including AlloSure Kidney and AlloMap Heart, which utilize donor-derived cell-free DNA to assess organ transplant health and identify potential rejections noninvasively. CareDx also provides various solutions for human leukocyte antigen typing, chimerism testing, and post-transplant monitoring. Its offerings extend to patient tracking software and predictive analysis tools, enhancing the overall transplant experience from initial matching to ongoing care. Founded in 1998 and headquartered in South San Francisco, California, CareDx has established partnerships for the development and distribution of advanced genomic testing technologies, further solidifying its role as a leader in transplant diagnostics.

Virdia, formerly known as HCL CleanTech, specializes in the development of cellulosic sugars and lignin derived from lignocellulosic biomass for applications in renewable chemicals, bio-energy, and nutrition. The company utilizes its proprietary CASE™ process, which efficiently converts a variety of feedstocks, including wood, energy crops, and agricultural residues, into refined sugars and lignin. This innovative, low-temperature method maximizes sugar yields while maintaining a minimal environmental impact through the nearly complete recycling of acids and solvents used during production. Virdia is guided by an experienced management team with extensive backgrounds in corn processing, chemicals, and biochemicals.

Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing breakthrough medicines for respiratory and allergic diseases. The company maintains a solid intellectual property position with its strong portfolio of novel therapeutic candidates now in clinical development and several pre-clinical programs. The two lead products are human recombinant proteins: Aerovantâ„¢, an IL-4 and -13 receptor antagonist which is in Phase IIa studies for asthma and Aerodermâ„¢, a PEGylated IL-4 and IL-13 receptor antagonist in pre-clinical studies for eczema.

Ikano Therapeutics a specialty pharmaceutical company, focuses on developing nasal spray drug products.

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company specializes in developing innovative treatments for hemophilia and other rare bleeding disorders, utilizing its engineered subcutaneous coagulation factors to promote blood clotting. This approach aims to address the inherent limitations of traditional intravenous treatments and improve patient outcomes. Catalyst's product portfolio includes Marzeptacog alfa (activated), an advanced coagulation Factor VIIa that has completed Phase II development for hemophilia A or B with inhibitors, and Dalcinonacog alfa, a next-generation Factor IX therapy that has finished Phase IIb clinical trials for hemophilia B. Additionally, the company is working on CB 2679d-GT, an early-stage gene therapy for hemophilia B, as well as other treatments targeting dry age-related macular degeneration and systemic complement inhibitors. Catalyst Biosciences has also formed strategic collaborations with Mosaic Biosciences and Biogen to enhance its research and development efforts in these therapeutic areas. The company was founded in 2002 and has a commitment to addressing unmet medical needs in coagulation and complement disorders.

Arete Therapeutics is a pharmaceutical company that develops small molecule therapeutics for diabetes and cardiovascular disease.

Osprey Pharmaceuticals USA, Inc. is a clinical-stage biotechnology company based in San Francisco, California, that specializes in developing protein therapeutics aimed at treating inflammatory and immune diseases. Founded in 2008, the company focuses on a pipeline of proprietary fusion protein therapeutics known as Leukocyte Population Modulators (LPMs). These therapeutics are designed to selectively target and neutralize chemokine-activated leukocytes, which play a crucial role in various inflammatory conditions. Osprey's lead candidate, CCL2-LPM, specifically targets the CCR2 chemokine receptor found on pathologically activated leukocytes and is currently undergoing a Phase Ib clinical trial for the treatment of IgA nephropathy, an inflammatory kidney disease.

BioImagene, Inc. specializes in digital pathology solutions tailored for clinical diagnostics and drug discovery. The company develops and distributes integrated hardware and software systems that facilitate the acquisition, viewing, sharing, management, archiving, and analysis of tissue images within pathology laboratories. BioImagene offers a range of immunohistochemistry (IHC) algorithms, including those for breast cancer (HER2, ER/PR, p53), Ki67 for various cancers, and specific markers for multiple myeloma and lymphoma. Their product lineup includes the iSlide input device, which allows pathologists to manipulate digital images of slides, and the iScan Coreo Au digital slide scanners, which support applications such as image analysis and telepathology. The company serves a diverse clientele, including cancer research laboratories, academic medical centers, community hospitals, reference laboratories, teaching hospitals, biotech firms, and pharmaceutical companies. Founded in 2003, BioImagene is headquartered in Sunnyvale, California.

Wellpartner is a prominent provider of pharmacy distribution solutions that serves health plans, Medicaid programs, and safety net organizations across the United States. The company specializes in managing 340B program services, focusing on innovative strategies that enhance pharmacy care while reducing medication costs. As the largest independent provider of contract pharmacy program services in the country, Wellpartner offers a range of services, including specialty pharmacy solutions and compliance support, aimed at maximizing the value of healthcare resources. By optimizing contract arrangements and ensuring access to specialty networks, Wellpartner helps healthcare organizations effectively serve more eligible patients and improve the overall quality of pharmacy care.

Gevo, Inc. is a renewable fuels company based in Englewood, Colorado, focused on developing and commercializing sustainable alternatives to petroleum-based products. Founded in 2005, Gevo specializes in producing renewable fuels such as gasoline, jet fuel, and diesel, as well as chemicals derived from isobutanol, a key product made from low-carbon renewable feedstocks. The company's offerings include renewable biodiesel, sustainable aviation fuel, isobutylene, ethanol, and animal feed. Gevo is also engaged in producing renewable electricity and natural gas to support its operations. Through its various segments, Gevo conducts research and development aimed at advancing biofuels and biochemicals, including innovative technologies for the production of sustainable aviation fuel and other renewable hydrocarbon products, while actively working to reduce greenhouse gas emissions.

NanoVasc is a pioneering medical device company specializing in the design and manufacture of biomimetic materials. These materials are engineered to be non-thrombogenic, durable, and capable of maintaining long-term patency. Utilizing an electrospinning process, NanoVasc produces scaffolds in various shapes and sizes, which are then customized with application-specific modifications on the scaffold's surface. These modifications are meticulously crafted to optimize device performance based on its intended deployment location. The company's flagship product is a synthetic vascular graft specifically developed for hemodialysis access. This innovative graft aims to improve patient outcomes by providing a reliable and effective alternative to traditional vascular access methods. NanoVasc's dedication to biomimetic design and precision engineering underscores its commitment to advancing medical solutions that enhance the quality of patient care in vascular health.

PrimeraDx, Inc. specializes in multiplexed infectious disease assays, focusing on advanced diagnostic technologies. The company offers Scalable Target Amplification Routine technology, enabling the simultaneous quantitative measurement of multiple target nucleic acids. Its product lineup includes ViraQuant, a multiplexed assay for the quantitative measurement of various viruses, as well as FungiQuant Yeast and FungiQuant Mold, which are fungal panels used in mycology testing. Additionally, PrimeraDx provides an instrument designed for the simultaneous detection and quantification of diverse target types, such as mRNA, miRNA, SNPs, and DNA. These products are utilized in various applications, including miRNA analysis, DNA methylation, quantitative genotyping, gene expression, and viral load measurement. Founded in 2004, PrimeraDx is headquartered in Mansfield, Massachusetts.

Chlorogen a biopharmaceutical company, engages in the development and manufacture of proteins for human therapy. The company, through its chloroplast transformation technology (CTT), offers plant made drugs for the treatment and prevention of human diseases, as well as for treatment of women's reproductive cancers. Its products include therapeutic proteins in tobacco that are made using chloroplast transformation technology. The chloroplast transformation technology facilitates hyper-expression of recombinant proteins in tobacco chloroplasts. The company offers its chloroplast-tobacco platform for commercial use in food and agriculture. Chlorogen, Inc. was founded in 2002 and is based in St. Louis, Missouri.

Light Sciences Oncology, Inc. is focused on developing and manufacturing talaporfin sodium, a water-soluble drug designed for the treatment of solid tumors. The company offers a single-use disposable device that employs LED technology to provide a fixed light dose, enhancing the effectiveness of the drug. Talaporfin sodium is utilized in treating various conditions, including hepatocellular carcinoma, metastatic colorectal cancer, and benign prostatic hyperplasia. Founded in 1994, Light Sciences Oncology is headquartered in Bellevue, Washington, and also engages in research and development services for oncology drugs.

Logical Therapeutics, Inc., a biopharmaceutical company, engages in the development of drugs to treat diseases caused by or associated with excessive inflammation. Its products include LT-NS001, a non-steroidal anti-inflammatory drug for the treatment of chronic inflammatory conditions, such as osteoarthritis; Leptin, a hormone for the regulation of normal body mass and metabolism; and TNF, a hormone that promotes the proliferation of hepatocytes. The company was founded in 2005 and is based in Waltham, Massachusetts.

Phytomedics is committed to quality, technological innovation and research. Their powerful portfolio of overlapping proprietary technologies is targeted to turning green plants into reliable vehicles for discovering and manufacturing proprietary botanical pharmaceuticals and nutraceuticals. NewLeadTM and RhizexTM elicitation and optimization processes greatly enhance the efficacy and reproducibility of plant-derived products and increase the synergy between various chemical components of plant extracts. The Company has developed an efficient and proprietary discovery and lead prioritization process based on high-power bio-informatics, high-tech data mining, efficient activity screening, and an extensive network of international collaborations.

Dreamerz Foods, Inc. provides various natural sleep products. It offers natural sleep beverage, a dietary supplement in the form of an all-natural, creamy, and dairy-based functional sleep beverage. The company also provides chocolate pillows, soothing dairy products, and herbal fruit-flavored mix. It offers its products through stores and online shops. Dreamerz Foods, Inc. was founded in 2006 and is based in San Francisco, California.

Arete Therapeutics is a pharmaceutical company that develops small molecule therapeutics for diabetes and cardiovascular disease.

The Natural Dentist, Inc., founded in 1995 and based in Medford, Massachusetts, specializes in manufacturing oral care products, including mouth rinses and toothpastes. The company, which was previously known as Woodstock Natural Products Inc. before rebranding in 2005, provides its products through various retail channels, including physical stores and online platforms. In 2010, The Natural Dentist was acquired by Revive Personal Products Company. The company is part of a broader portfolio that includes over-the-counter consumer healthcare brands, reflecting its commitment to promoting oral health and hygiene.

Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing breakthrough medicines for respiratory and allergic diseases. The company maintains a solid intellectual property position with its strong portfolio of novel therapeutic candidates now in clinical development and several pre-clinical programs. The two lead products are human recombinant proteins: Aerovantâ„¢, an IL-4 and -13 receptor antagonist which is in Phase IIa studies for asthma and Aerodermâ„¢, a PEGylated IL-4 and IL-13 receptor antagonist in pre-clinical studies for eczema.

Attune Foods, Inc. is a producer of organic snacks, headquartered in San Francisco, California, with additional operations in Eugene, Oregon. Established in 2006, the company specializes in probiotic wellness bars available in a variety of flavors, including dark chocolate, chocolate crisp, and mint chocolate, among others. In addition to these bars, Attune Foods offers a range of products such as granolas featuring chocolate or yogurt chips, muesli, cereal products, and graham crackers. The company's focus is on providing customized healthy food options to support consumer wellness.

Endocyte, Inc. is a biopharmaceutical company focused on developing receptor-targeted therapies for cancer and inflammatory diseases. Headquartered in West Lafayette, Indiana, the company creates innovative small molecule drug conjugates (SMDCs) and companion imaging agents. Among its key products, Vintafolide is in Phase IIb clinical trials for non-small cell lung cancer, while EC1456 and EC1169 are in Phase I trials for advanced solid tumors and metastatic castration-resistant prostate cancer, respectively. Additionally, Endocyte is developing several pre-clinical candidates, including EC2629 for cancer treatment and EC2319 for inflammatory diseases. The company has established collaborations with Purdue Research Foundation and other organizations to advance its pipeline. Founded in 1995, Endocyte operates as a subsidiary of Novartis AG.

ProteoGenix is a company focused on the development and commercialization of diagnostic testing products aimed at the maternal-fetal health sector. Founded in 2002 and headquartered in Costa Mesa, California, with additional offices in Beaverton, Oregon, and Orange County, California, ProteoGenix specializes in non-invasive diagnostic tests. These tests are designed to detect various conditions including intraamniotic infection, neonatal sepsis, preterm birth, preeclampsia, and Down syndrome. The company's efforts are directed towards enhancing maternal-fetal health outcomes through innovative diagnostic solutions.

diaDexus is a privately held biotechnology company based in the United States, specializing in the discovery, development, and commercialization of diagnostic products. The company is known for its lead product, the PLAC Test, which measures Lp-PLA2, an enzyme linked to vascular inflammation and critical in assessing the risk of coronary heart disease and ischemic stroke associated with atherosclerosis. This test is notable for being the only FDA-cleared blood test designed to aid in risk assessment for these cardiovascular conditions. In addition to the PLAC Test, diaDexus develops a range of diagnostic test kits for various health conditions, including liver disease, cancer markers, renal disease, diabetes, and electrolyte imbalances. The company primarily operates in the United States, with additional presence in Europe and other regions, contributing to its overall revenue.

Dreamerz Foods, Inc. provides various natural sleep products. It offers natural sleep beverage, a dietary supplement in the form of an all-natural, creamy, and dairy-based functional sleep beverage. The company also provides chocolate pillows, soothing dairy products, and herbal fruit-flavored mix. It offers its products through stores and online shops. Dreamerz Foods, Inc. was founded in 2006 and is based in San Francisco, California.

The Natural Dentist, Inc., founded in 1995 and based in Medford, Massachusetts, specializes in manufacturing oral care products, including mouth rinses and toothpastes. The company, which was previously known as Woodstock Natural Products Inc. before rebranding in 2005, provides its products through various retail channels, including physical stores and online platforms. In 2010, The Natural Dentist was acquired by Revive Personal Products Company. The company is part of a broader portfolio that includes over-the-counter consumer healthcare brands, reflecting its commitment to promoting oral health and hygiene.

Neurotech is a privately held biotechnology company focused on developing innovative therapies for chronic retinal diseases, addressing significant unmet medical needs in the ophthalmology market. The company has created a novel ocular implant that facilitates the continuous production of therapeutic proteins directly in the eye. This system is designed to help therapeutic cells survive in challenging conditions, thereby replacing or supporting the function of deteriorating target cells or tissues. By enhancing the treatment options available for eye diseases, Neurotech aims to improve the quality of life for patients suffering from these conditions.

Endocyte, Inc. is a biopharmaceutical company focused on developing receptor-targeted therapies for cancer and inflammatory diseases. Headquartered in West Lafayette, Indiana, the company creates innovative small molecule drug conjugates (SMDCs) and companion imaging agents. Among its key products, Vintafolide is in Phase IIb clinical trials for non-small cell lung cancer, while EC1456 and EC1169 are in Phase I trials for advanced solid tumors and metastatic castration-resistant prostate cancer, respectively. Additionally, Endocyte is developing several pre-clinical candidates, including EC2629 for cancer treatment and EC2319 for inflammatory diseases. The company has established collaborations with Purdue Research Foundation and other organizations to advance its pipeline. Founded in 1995, Endocyte operates as a subsidiary of Novartis AG.

Morphotek, established in 2000, is a prominent life science company specializing in developing novel biological products to combat cancer, inflammation, and infectious diseases. The company's core technology, morphogenics, was co-invented by its current President and CEO, Dr. Nicholas Nicolaides, during his postgraduate research at Johns Hopkins Medical School. Morphotek focuses on discovering and developing monoclonal antibodies (mAbs) using this proprietary technology to treat various conditions such as ovarian and pancreatic cancers, rheumatoid arthritis, and asthma. The company conducts independent research and clinical development programs for its drug candidates.

Cardiokine, Inc. is a specialty pharmaceutical company based in Philadelphia, Pennsylvania, focused on developing pharmaceuticals aimed at preventing and treating cardiovascular diseases. Founded in 2004, the company is known for its lead product, lixivaptan, an orally active vasopressin receptor antagonist designed for patients with congestive heart failure who experience hyponatremia. Cardiokine is committed to advancing innovative therapies to address heart failure and related cardiovascular conditions.

Sciona provides gene-based personalized health and nutrition analysis and recommendations based on individual diet, lifestyle, and genetic profile. The company's Mycellf Program, which includes a diet and lifestyle questionnaire, makes recommendations for how individuals can make choices that benefit their long-term health. It also offers genetic testing products, which address personal wellness, fitness, and nutritional issues. The company was founded in 2000 and is headquartered in Aurora, Colorado.

Chromatin is a biotech company developing and marketing innovative technologies and products that benefit the agricultural, energy, chemical, nutritional, and pharmaceutical sectors. Chromatin is unlocking the potential of plants to produce greater value and meaningful products for consumers, growers, seed producers, and bioprocessors. Chromatin is commercializing solutions that proactively address key societal challenges such as improving agricultural productivity and increasing renewable energy resources.

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company specializes in developing innovative treatments for hemophilia and other rare bleeding disorders, utilizing its engineered subcutaneous coagulation factors to promote blood clotting. This approach aims to address the inherent limitations of traditional intravenous treatments and improve patient outcomes. Catalyst's product portfolio includes Marzeptacog alfa (activated), an advanced coagulation Factor VIIa that has completed Phase II development for hemophilia A or B with inhibitors, and Dalcinonacog alfa, a next-generation Factor IX therapy that has finished Phase IIb clinical trials for hemophilia B. Additionally, the company is working on CB 2679d-GT, an early-stage gene therapy for hemophilia B, as well as other treatments targeting dry age-related macular degeneration and systemic complement inhibitors. Catalyst Biosciences has also formed strategic collaborations with Mosaic Biosciences and Biogen to enhance its research and development efforts in these therapeutic areas. The company was founded in 2002 and has a commitment to addressing unmet medical needs in coagulation and complement disorders.

Adlyfe is a biotechnology company established in 2003 that specializes in developing innovative diagnostic products for neurodegenerative diseases. The company focuses on creating biomarkers and diagnostic tests aimed at detecting amyloid diseases, which are linked to the misfolding and aggregation of proteins in the brain. This process, known as amyloidogenesis, leads to the accumulation of harmful proteins that can cause the loss of neural cells and brain tissue, resulting in conditions such as dementia and motor dysfunction. By offering diagnostic solutions for diseases like sporadic and variant Creutzfeldt-Jakob disease, Adlyfe aims to improve patient health outcomes through early detection and intervention.

Ikano Therapeutics a specialty pharmaceutical company, focuses on developing nasal spray drug products.

CareDx, Inc. is a precision medicine company that specializes in developing and commercializing innovative healthcare solutions for transplant patients and their caregivers. The company offers a range of molecular diagnostics products, including AlloSure Kidney and AlloMap Heart, which utilize donor-derived cell-free DNA to assess organ transplant health and identify potential rejections noninvasively. CareDx also provides various solutions for human leukocyte antigen typing, chimerism testing, and post-transplant monitoring. Its offerings extend to patient tracking software and predictive analysis tools, enhancing the overall transplant experience from initial matching to ongoing care. Founded in 1998 and headquartered in South San Francisco, California, CareDx has established partnerships for the development and distribution of advanced genomic testing technologies, further solidifying its role as a leader in transplant diagnostics.

Alinea Pharmaceuticals, Inc., a biopharmaceutical company previously focused on developing new therapeutics for the treatment of diabetes and other metabolic disorders.

Chlorogen a biopharmaceutical company, engages in the development and manufacture of proteins for human therapy. The company, through its chloroplast transformation technology (CTT), offers plant made drugs for the treatment and prevention of human diseases, as well as for treatment of women's reproductive cancers. Its products include therapeutic proteins in tobacco that are made using chloroplast transformation technology. The chloroplast transformation technology facilitates hyper-expression of recombinant proteins in tobacco chloroplasts. The company offers its chloroplast-tobacco platform for commercial use in food and agriculture. Chlorogen, Inc. was founded in 2002 and is based in St. Louis, Missouri.

BioMimetic Therapeutics is a biotechnology company focused on developing biologically active drug-device combination products that stimulate the body's natural tissue regenerative processes. Founded in 1999 and headquartered in Franklin, Tennessee, the company offers a range of products targeting various orthopedic and sports medicine conditions. These include Augment Injectable and Augment Rotator Cuff, which are designed for applications such as foot and ankle fusions, wrist fracture healing, and rotator cuff tear surgical treatment. Additionally, the Augment Tendinopathy Injection addresses injuries related to tendon overuse. Through its innovative approaches, BioMimetic Therapeutics aims to improve healing outcomes for patients with skeletal and associated tissue injuries.

Brand New Brands is a groundbreaking new company that brings together the entrepreneurial spirit of a start-up and the resources of an established corporation to create new foods and beverages that promote health and wellness. Brand New Brands uses a portfolio-based incubator model to develop and market the highest potential new functional food business opportunities for the U.S. marketplace. Core to their approach is the commitment to create food and beverage products that are efficacious (by medical standards), honest and transparent in their claims, and satisfying to eat or drink. By vetting and assessing the potential of scores of new product concepts, they take the most promising opportunities and fuse them with talented, passionate and proven entrepreneurial teams who turn ideas into thriving new ventures. They focus their efforts and resources by innovating “category-creating” brand platforms that are capable of crossing over from niche markets to the mainstream in three to five years. They only pursue opportunities where they can claim distinct competitive advantages over large food companies through IP, brand creation or non-traditional distribution. Their strategy is to take the most promising new nutritional technologies and deliver them to the marketplace through great-tasting products with engaging “lifestyle” brands that educate and attract loyal customers and progressive retail partners. They take opportunities to market that are likely to scale quickly due to the convergence of scientific advances, consumer readiness and media attention.

Alexza Pharmaceuticals, Inc. is a pharmaceutical company based in Mountain View, California, dedicated to the research, development, and commercialization of proprietary products for the acute treatment of central nervous system conditions. The company utilizes its innovative Staccato system, a hand-held inhaler that vaporizes drugs into a condensation aerosol for rapid systemic delivery when inhaled. Its primary product, ADASUVE, contains Staccato loxapine and is intended for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. Additionally, Alexza is developing AZ-002, which is Staccato alprazolam for acute repetitive seizures, and AZ-007, Staccato zaleplon for insomnia. The company was founded in 2001 and was formerly known as Alexza Molecular Delivery Corporation before rebranding in 2005. As of 2016, it operates as a subsidiary of Ferrer Therapeutics, Inc.

CareDx, Inc. is a precision medicine company that specializes in developing and commercializing innovative healthcare solutions for transplant patients and their caregivers. The company offers a range of molecular diagnostics products, including AlloSure Kidney and AlloMap Heart, which utilize donor-derived cell-free DNA to assess organ transplant health and identify potential rejections noninvasively. CareDx also provides various solutions for human leukocyte antigen typing, chimerism testing, and post-transplant monitoring. Its offerings extend to patient tracking software and predictive analysis tools, enhancing the overall transplant experience from initial matching to ongoing care. Founded in 1998 and headquartered in South San Francisco, California, CareDx has established partnerships for the development and distribution of advanced genomic testing technologies, further solidifying its role as a leader in transplant diagnostics.

Neosil, Inc. is a pharmaceutical company specializing in dermatology. It has developed a topical hair growth product and is also working on a broad-spectrum topical anti-microbial agent aimed at treating acne and other infections. Neosil's core technology offers extensive anti-infective capabilities, characterized by a long duration of effectiveness and flexible formulation options.

BioMimetic Therapeutics is a biotechnology company focused on developing biologically active drug-device combination products that stimulate the body's natural tissue regenerative processes. Founded in 1999 and headquartered in Franklin, Tennessee, the company offers a range of products targeting various orthopedic and sports medicine conditions. These include Augment Injectable and Augment Rotator Cuff, which are designed for applications such as foot and ankle fusions, wrist fracture healing, and rotator cuff tear surgical treatment. Additionally, the Augment Tendinopathy Injection addresses injuries related to tendon overuse. Through its innovative approaches, BioMimetic Therapeutics aims to improve healing outcomes for patients with skeletal and associated tissue injuries.

Sciona provides gene-based personalized health and nutrition analysis and recommendations based on individual diet, lifestyle, and genetic profile. The company's Mycellf Program, which includes a diet and lifestyle questionnaire, makes recommendations for how individuals can make choices that benefit their long-term health. It also offers genetic testing products, which address personal wellness, fitness, and nutritional issues. The company was founded in 2000 and is headquartered in Aurora, Colorado.

Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing breakthrough medicines for respiratory and allergic diseases. The company maintains a solid intellectual property position with its strong portfolio of novel therapeutic candidates now in clinical development and several pre-clinical programs. The two lead products are human recombinant proteins: Aerovantâ„¢, an IL-4 and -13 receptor antagonist which is in Phase IIa studies for asthma and Aerodermâ„¢, a PEGylated IL-4 and IL-13 receptor antagonist in pre-clinical studies for eczema.

Nucleonics is a biotechnology company focused on RNA interference-based therapeutics.

Efficas, Inc., based in Boulder, Colorado, is a health science and technology company that specializes in the research, development, and commercialization of products aimed at nutritional management of the immune system for both humans and pets. Founded in 2003, the company offers EFFICAS CARE, a berry-flavored non-prescription medical food designed to assist in the dietary management of asthma and related allergies. Efficas focuses on creating effective solutions that work with the body's natural systems, providing safe and significant health benefits to patients suffering from asthma and allergic conditions.

Cardiokine, Inc. is a specialty pharmaceutical company based in Philadelphia, Pennsylvania, focused on developing pharmaceuticals aimed at preventing and treating cardiovascular diseases. Founded in 2004, the company is known for its lead product, lixivaptan, an orally active vasopressin receptor antagonist designed for patients with congestive heart failure who experience hyponatremia. Cardiokine is committed to advancing innovative therapies to address heart failure and related cardiovascular conditions.

Spectral Genomics, based in Houston, Texas, specializes in developing innovative products and services in the field of molecular genetics and diagnostics. The company is recognized for its pioneering technology in genomic profiling, offering services tailored for both academic and industrial research laboratories. By focusing on human genetics, Spectral Genomics aims to advance the understanding of genetic information and its applications in various research contexts.

Morphotek, established in 2000, is a prominent life science company specializing in developing novel biological products to combat cancer, inflammation, and infectious diseases. The company's core technology, morphogenics, was co-invented by its current President and CEO, Dr. Nicholas Nicolaides, during his postgraduate research at Johns Hopkins Medical School. Morphotek focuses on discovering and developing monoclonal antibodies (mAbs) using this proprietary technology to treat various conditions such as ovarian and pancreatic cancers, rheumatoid arthritis, and asthma. The company conducts independent research and clinical development programs for its drug candidates.

Phytomedics is committed to quality, technological innovation and research. Their powerful portfolio of overlapping proprietary technologies is targeted to turning green plants into reliable vehicles for discovering and manufacturing proprietary botanical pharmaceuticals and nutraceuticals. NewLeadTM and RhizexTM elicitation and optimization processes greatly enhance the efficacy and reproducibility of plant-derived products and increase the synergy between various chemical components of plant extracts. The Company has developed an efficient and proprietary discovery and lead prioritization process based on high-power bio-informatics, high-tech data mining, efficient activity screening, and an extensive network of international collaborations.

Immunicon develops and commercializes proprietary cell-based diagnostic and research products, primarily focusing on cancer. The company aims to enhance clinical outcomes by providing physicians with improved information for the understanding, diagnosis, treatment, and monitoring of cancer. Its technologies, branded as CellTracks, are designed to identify, count, and characterize small numbers of tumor cells present in blood samples, offering clinically meaningful insights earlier than traditional diagnostic methods. Collaborating with Veridex, LLC, a Johnson & Johnson company, Immunicon contributed to the development of the CellSearch Epithelial Cell Kit, which was submitted for FDA approval for managing metastatic breast cancer. Immunicon anticipates that this kit will be the first product launched based on its technologies. The company also sees potential applications for its technologies in cancer diagnostics, drug development, and research, as well as in other medical fields such as cardiovascular and infectious diseases.

BioMimetic Therapeutics is a biotechnology company focused on developing biologically active drug-device combination products that stimulate the body's natural tissue regenerative processes. Founded in 1999 and headquartered in Franklin, Tennessee, the company offers a range of products targeting various orthopedic and sports medicine conditions. These include Augment Injectable and Augment Rotator Cuff, which are designed for applications such as foot and ankle fusions, wrist fracture healing, and rotator cuff tear surgical treatment. Additionally, the Augment Tendinopathy Injection addresses injuries related to tendon overuse. Through its innovative approaches, BioMimetic Therapeutics aims to improve healing outcomes for patients with skeletal and associated tissue injuries.

Emerald BioAgriculture Corporation is a privately held company based in Hockessin, Delaware, that focuses on developing specialty nutritional technologies and naturally occurring biochemicals aimed at enhancing crop production. Founded in 1994, the company creates products designed to improve crop yields, quality, and disease control for agricultural product manufacturers. With a commitment to innovation, Emerald BioAgriculture provides solutions that support sustainable agricultural practices globally.

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company specializes in developing innovative treatments for hemophilia and other rare bleeding disorders, utilizing its engineered subcutaneous coagulation factors to promote blood clotting. This approach aims to address the inherent limitations of traditional intravenous treatments and improve patient outcomes. Catalyst's product portfolio includes Marzeptacog alfa (activated), an advanced coagulation Factor VIIa that has completed Phase II development for hemophilia A or B with inhibitors, and Dalcinonacog alfa, a next-generation Factor IX therapy that has finished Phase IIb clinical trials for hemophilia B. Additionally, the company is working on CB 2679d-GT, an early-stage gene therapy for hemophilia B, as well as other treatments targeting dry age-related macular degeneration and systemic complement inhibitors. Catalyst Biosciences has also formed strategic collaborations with Mosaic Biosciences and Biogen to enhance its research and development efforts in these therapeutic areas. The company was founded in 2002 and has a commitment to addressing unmet medical needs in coagulation and complement disorders.

Alexza Pharmaceuticals, Inc. is a pharmaceutical company based in Mountain View, California, dedicated to the research, development, and commercialization of proprietary products for the acute treatment of central nervous system conditions. The company utilizes its innovative Staccato system, a hand-held inhaler that vaporizes drugs into a condensation aerosol for rapid systemic delivery when inhaled. Its primary product, ADASUVE, contains Staccato loxapine and is intended for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. Additionally, Alexza is developing AZ-002, which is Staccato alprazolam for acute repetitive seizures, and AZ-007, Staccato zaleplon for insomnia. The company was founded in 2001 and was formerly known as Alexza Molecular Delivery Corporation before rebranding in 2005. As of 2016, it operates as a subsidiary of Ferrer Therapeutics, Inc.

GeneFormatics is a biotechnology company that focuses on structural proteomics. It develops innovative function prediction methods aimed at the rapid identification of biologically relevant targets from extensive sequence data generated by global genomics projects. By harnessing advanced computational techniques, GeneFormatics contributes to the understanding of protein structures and functions, facilitating breakthroughs in biological research and potential therapeutic applications.

Morphotek, established in 2000, is a prominent life science company specializing in developing novel biological products to combat cancer, inflammation, and infectious diseases. The company's core technology, morphogenics, was co-invented by its current President and CEO, Dr. Nicholas Nicolaides, during his postgraduate research at Johns Hopkins Medical School. Morphotek focuses on discovering and developing monoclonal antibodies (mAbs) using this proprietary technology to treat various conditions such as ovarian and pancreatic cancers, rheumatoid arthritis, and asthma. The company conducts independent research and clinical development programs for its drug candidates.

Corus Pharma is a biotech and specialty drug company that focuses on respiratory and infectious diseases. In other words, it is a development stage biopharmaceutical company that focuses on the development and commercialization of novel applications and formulations of known therapeutics to treat severe respiratory diseases. The products of the company are Corus 1020 and 1030. Corus 1020 is designed to treat respiratory infections in cystic fibrosis patients, using an inhalable form of an antibiotic called aztreonam. Corus 1030 is inhaled lidocaine for the treatment of patients suffering from the severe persistent forms of asthma. Corus Pharma is a U.S.-based company that was founded in 2001 and the company was acquired by Gilead Sciences on October 22, 2006.

BioMimetic Therapeutics is a biotechnology company focused on developing biologically active drug-device combination products that stimulate the body's natural tissue regenerative processes. Founded in 1999 and headquartered in Franklin, Tennessee, the company offers a range of products targeting various orthopedic and sports medicine conditions. These include Augment Injectable and Augment Rotator Cuff, which are designed for applications such as foot and ankle fusions, wrist fracture healing, and rotator cuff tear surgical treatment. Additionally, the Augment Tendinopathy Injection addresses injuries related to tendon overuse. Through its innovative approaches, BioMimetic Therapeutics aims to improve healing outcomes for patients with skeletal and associated tissue injuries.

Bruker Corporation is a leading provider of high-performance scientific instruments and solutions tailored for molecular and materials research, as well as industrial and applied analysis. The company manufactures a range of scientific instruments and diagnostic tests primarily for clients in the life sciences, pharmaceutical, and biotechnology sectors. Bruker operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST), with the BSI CALID segment generating the highest revenue. The company has a significant revenue presence in the Asia Pacific region, reflecting its global reach and commitment to advancing scientific research and innovation. Additionally, Bruker Cellular Analysis focuses on cell biology, facilitating the exploration of cellular phenomes and the mastery of single-cell analysis for laboratories.

Circe Biomedical, Inc. is a company focused on developing, producing, and commercializing bioartificial organ systems. It specializes in creating bioartificial organs using isolated mammalian cells and membranes to address the needs of patients with acute, end-stage liver failure. One of its notable products is the HepatAssist® Liver Support System, which combines viable liver cells with biocompatible membranes to function as an extracorporeal liver assist system. Additionally, Circe Biomedical is working on the PancreAssist System, an implantable bioartificial pancreas designed for individuals with severe insulin-dependent diabetes. Founded in 1999, the company is headquartered in Lexington, Massachusetts.

GeneFormatics is a biotechnology company that focuses on structural proteomics. It develops innovative function prediction methods aimed at the rapid identification of biologically relevant targets from extensive sequence data generated by global genomics projects. By harnessing advanced computational techniques, GeneFormatics contributes to the understanding of protein structures and functions, facilitating breakthroughs in biological research and potential therapeutic applications.

In December 1999, Pangea Systems became DoubleTwist, Inc. - a new application service provider (ASP)/ Internet company devoted to empowering life scientists. The change reflects a new focus on this Internet portal. DoubleTwist.com integrates powerful tools and data behind automated research agents that retrieve and interpret data based on the user's scientific questions. The company's traditional data warehousing and mining software power the site, enabling life science research through an easy-to-use interface on the Web. DoubleTwist has established a talented and experienced development team of scientific and technical personnel dedicated to building software solutions that address the biological data management needs of life scientists. DoubleTwist's scientific team is comprised of leading experts in their respective fields of biochemistry, molecular biology, protein chemistry, bioinformatics, computer science and computational biology. They come to DoubleTwist from world-renowned institutions, including Stanford University, UCLA, UC Berkeley, UCSF, University of Pennsylvania, Sandoz Pharmaceutical, Onyx Pharmaceutical, Incyte, Molecular Simulations, Molecular Dynamics, Roche and Glaxo Wellcome. The company's software engineers have extensive experience in commercial-grade software systems, with particular expertise in relational database and object-oriented development. They come to DoubleTwist from some of the industry's most successful companies, including Apple, Oracle and IBM.